Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
This is an open-label treatment program following basic prescribing information for patients with recurrent UPSC (Uterine Papillary Serous Carcinoma) to provide access to everolimus and limited treatment alternatives.
Uterine Cancer
DRUG: Letrozole|DRUG: Everolimus
Single Arm Trial With Combination of Everolimus and Letrozole in Treatment With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation; Tumor Response to treatment with Everolimus and Letrozole using RECIST Criteria, Tumor Response to treatment with Everolimus and Letrozole using RECIST Criteria, Baseline, Then every 12 weeks while on Everolimus and Letrozole up to 36 months;
Single Arm Trial With Combination of Everolimus and Letrozole in Treatment With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation; Overall survival of patients treated with the combination of letrozole and everolimus, Overall survival of patients treated with the combination of letrozole and everolimus, From randomization until date of death, assessed up to 36 months
The objective is to provide access to everolimus for patients with Recurrent UPSC and limited treatment alternatives.

Letrozole 2.5mg daily q 30 days Everolimus 10mg daily q 28 days